ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 318

Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic

Francine Castillo1, Michael Dodge 1, Jung Hee Noh 2, Laura Trupin 1, Jinoos Yazdany 3 and Sarah Goglin 3, 1University of California, San Francisco, San Francisco, CA, 2Zuckerberg San Francisco General Hospital, San Francisco, CA, 3UCSF Division of Rheumatology, San Francisco, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: hydroxychloroquine and systemic lupus erythematosus (SLE), quality improvement

Session Information

Date: Sunday, November 10, 2019

Title: Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and with prolonged use. In 2016, the American Academy of Ophthalmology (AAO) modified its HCQ dosing and screening guidelines to recommend a maximum daily dose of 5 mg/kg of actual body weight and retinal examinations at baseline, then annually after 5 years of taking HCQ. We undertook a quality improvement project in a safety net rheumatology clinic that had two aims: 1) to increase the proportion of patients prescribed hydroxychloroquine at recommended doses from 85% at baseline to 95% and 2) to improve the proportion of patients receiving appropriate retinal screening from 52% at baseline to 80% at one year. 

Methods: Using the Institute for Healthcare Improvement’s Model for Improvement, we first mapped the existing clinical workflow for HCQ prescribing and monitoring. We developed and applied two process measures to track our progress: the proportion of patients prescribed hydroxychloroquine receiving a dose less than or equal to 5 mg/kg at their last encounter and the proportion of patients prescribed hydroxychloroquine at their last encounter with a retinal screening test over the last 18 months.  After identifying baseline values for our two process measures, we worked with clinicians and clinic support staff over four Plan-Do-Study-Act (PDSA) cycles to develop our intervention. The final optimized workflow involved the clinic’s nurse using a weekly report to identify patients who were overdue for retinal screening for an ophthalmology referral and to alert physicians whose patients were on a higher than recommended dose of HCQ.  In September 2018, we queried the electronic health record again for data on our clinic’s adherence rates to AAO guidelines between September 2017 to August 2018 to analyze the impact of our intervention.

Results: The percentage of clinic patients prescribed HCQ at doses less than 5.0 mg/kg daily increased from 84% to 86% during the study period, and the percentage receiving retinal screening increased from 64% to 76%. Of note, only 8 out of the 243 SLE patients on HCQ with a rheumatology office visit in 2018 did not have an ophthalmology appointment scheduled. The remainder of those that did not have retinal screening had an ophthalmology appointment scheduled, but either cancelled or did not appear to their appointments.

Conclusion: Using the Model for Improvement, we were able to develop and integrate an intervention to increase adherence to the AAO recommendations for HCQ dosing and retinal screening measures, although we fell short of our pre-specified improvement goals. Although the intervention has been moderately effective at improving patient safety practices for this drug, efforts are ongoing to further understand barriers to further improvement, including root cause analysis of individual-level and systems-level factors.


Figure 1_ACR 2019_Castillo_Dodge

Figure 1: Distribution of hydroxychloroquine doses prescribed to rheumatology clinic patients in the periods prior to and after intervention.


Figure 2_ACR 2019_Castillo_Dodge

Figure 2: Frequency of retinal screenings among rheumatology clinic patients treated with hydroxychloroquine in the periods prior to and after intervention.


Disclosure: F. Castillo, None; M. Dodge, None; J. Noh, None; L. Trupin, None; J. Yazdany, Astra Zeneca, 5, Pfizer, 2; S. Goglin, None.

To cite this abstract in AMA style:

Castillo F, Dodge M, Noh J, Trupin L, Yazdany J, Goglin S. Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improving-safe-prescribing-of-hydroxychloroquine-in-a-safety-net-hospital-rheumatology-clinic/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-safe-prescribing-of-hydroxychloroquine-in-a-safety-net-hospital-rheumatology-clinic/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology